New drug combo shows promise for Hard-to-Treat lymphoma

NCT ID NCT03075696

Ongoing Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 30, 2026 · Updated 3 times

Summary

This study tests a new drug called glofitamab, given alone or with obinutuzumab, in people with B-cell non-Hodgkin's lymphoma that has come back or not responded to prior treatments. The trial has three parts to find the best dose and check safety and effectiveness. About 940 participants are expected to take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: glofitamab (a type of immunotherapy) given with obinutuzumab
What this could lead to: If successful, this could offer a new treatment option for people with B-cell non-Hodgkin's lymphoma that has not responded to other therapies.
What could go wrong: This is an early-phase trial (Phase I/II) with dose escalation, so safety and effectiveness are not yet proven. Side effects, including severe immune reactions, are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell non-Hodgkin lymphoma non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-HODGKIN'S LYMPHOMA

Contacts and locations

Locations

AUSL della Romagna

Ravenna, Emilia-Romagna, 48121, Italy
Allegheny Health Network (Pittsburg PA)

Pittsburgh, Pennsylvania, 15212, United States
Auckland Cancer Trial Centre

Auckland, 1023, New Zealand
CHU DE RENNES - CHU Pontchaillou

Rennes, 35033, France
CHU Saint Eloi

Montpellier, 34295, France
Ch Lyon Sud

Pierre-Bénite, 69495, France
China Medical University Hospital

Taichung, 404, Taiwan
Cliniques Universitaires St-Luc

Brussels, 1200, Belgium
Fond. IRCCS Istituto Nazionale Tumori

Milan, Lombardy, 20133, Italy
Helsinki University Central Hospital

Helsinki, 00029, Finland
Hopital Claude Huriez

Lille, 59037, France
Hopital Henri Mondor

Créteil, 94010, France
Hospital Duran i Reynals L'Hospitalet

L'Hospitalet de Llobregat, Barcelona, 08908, Spain
Hospital Univ. 12 de Octubre

Madrid, 28041, Spain
Hospital Universitari Germans Trias i Pujol

Badalona, Barcelona, 08915, Spain
Hospital Universitari Vall d'Hebron

Barcelona, 08035, Spain
Hospital Universitario Marques de Valdecilla

Santander, Cantabria, 39008, Spain
Hospital del Mar

Barcelona, 08003, Spain
Istituto Clinico Humanitas

Rozzano, Lombardy, 20089, Italy
MSKCC

New York, New York, 10065, United States
Mount Sinai Medical Center

New York, New York, 10029, United States
National Taiwan Universtiy Hospital

Taipei, 100, Taiwan
Peter Maccallum Cancer Centre

Melbourne, Victoria, 3000, Australia
Prince of Wales Hospital

Randwick, New South Wales, 2031, Australia
Princess Margaret Cancer Center

Toronto, Ontario, M5G 1Z5, Canada
Rigshospitalet

København Ø, 2100, Denmark
Swedish Cancer Inst.

Seattle, Washington, 98104, United States
UZ Gent

Ghent, 9000, Belgium
University of Michigan

Ann Arbor, Michigan, 48109-0934, United States
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu

Wroc?aw, 50-367, Poland
Uniwersytecki Szpital Kliniczny w Poznaniu

Późna, 60-569, Poland
Uniwersyteckie Centrum Kliniczne

Gda?sk, 80-214, Poland
Vseobecna Fakultni Nemocnice v Praze, I. Interni Klinika - Klinika Hematoonkologie VFN a 1. LF UK

Prague, 128 08, Czechia
Washington University

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.